Advanced Medical Solutions Grp PLC Director/PDMR Shareholding (9007N)

TIDMAMS

RNS Number : 9007N

Advanced Medical Solutions Grp PLC

27 September 2023

 
   27 September 2023 
 

Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

Director/PDMR Shareholding

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies , announces th at it was notified on 25 September 2023 that on the same day, Chris Meredith, Director, purchased 23,000 ordinary shares of 5p each ("Ordinary Shares") at a price of 192.37p per Ordinary Share and that Eddie Johnson, Director, purchased 21,174 Ordinary Shares of 5p each at a price of 193.6p per Ordinary Share.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1.   Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name: (i) Chris Meredith 
       (ii) Eddie Johnson 
     --------------------------------------------------------------------- 
 2.   Reason for the notification 
     --------------------------------------------------------------------- 
 a)   Position/status: (i) Chief Executive Officer 
       (ii) Chief Financial Officer 
     --------------------------------------------------------------------- 
 b)   Initial notification/Amendment: Initial Notification 
     --------------------------------------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     --------------------------------------------------------------------- 
 a)   Name: Advanced Medical Solutions Group plc 
     --------------------------------------------------------------------- 
 b)   LEI: 213800HJP6OWOSZI1L74 
     --------------------------------------------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     --------------------------------------------------------------------- 
 a)   Description of the financial instrument, type of instrument: 
       Ordinary Shares of 5p 
       Identification code: GB0004536594 
     --------------------------------------------------------------------- 
 b)        Nature of the transactions: 
             *    Purchase of Ordinary Shares 
     --------------------------------------------------------------------- 
 c)   Price(s) and volume(s): Price(s)                 Volume(s) 
        (i) 192.37p per share    23,000 
                                ---------- 
        (ii) 193.6p per share    21,174 
                                ---------- 
     --------------------------------------------------------------------- 
 d)   Aggregated information: 
       N/A 
     --------------------------------------------------------------------- 
 e)   Date of the transaction: 25/09/2023 
     --------------------------------------------------------------------- 
 f)   Place of the transaction: London Stock Exchange, AIM 
       Market (XLON) 
     --------------------------------------------------------------------- 
 

- End -

For further information, please visit www.admedsol.com or contact:

 
 Advanced Medical Solutions Group plc            Tel: [phone] 
                                                            545508 
 Chris Meredith, Chief Executive Officer 
  Eddie Johnson, Chief Financial Officer 
  Michael King, Investor Relations 
 
 Consilium Strategic Communications           Tel: [phone] 
                                                              5700 
 Matthew Neal / Lucy Featherstone          [e-mail] 
 
 Investec Bank PLC (NOMAD & Broker)           Tel: [phone] 
                                                              5970 
 Gary Clarence / David Anderson 
 HSBC Bank plc (Broker)                        Tel: [phone] 
                                                              8888 
 Sam McLennan / Joe Weaving / Stephanie 
  Cornish 
 

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand(R) , RESORBA(R) , LiquiBandFix8(R) and Seal-G(R) . AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal(R) brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more

information, please see   www.admedsol.com . 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHKZGZLVNZGFZM

(END) Dow Jones Newswires

September 27, 2023 12:55 ET (16:55 GMT)